GCGiorgio Cartechini

Giorgio Cartechini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giorgio Cartechini has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A posteriori and predictive interplay evaluation methodology for lung and esophageal cancer patients treated in free breathing with IMPT

    by Giorgio Cartechini, Esther Kneepkens, Gloria Vilches-Freixas, Indra Lubken, Marije Velders, Sebastiaan Nijsten, Mirko Unipan, Ilaria Rinaldi

    Objective. Pencil beam scanning proton therapy is sensitive to respiratory motion, leading to potential dose inhomogeneities due to interplay effects. We developed and validated a predictive framework to assess interplay and motion robustness in lung and esophageal cancer patients treated under free-breathing conditions. Approach. A synthetic-breathing-based predictive model was implemented in the RayStation treatment planning system and validated against an a posteriori approach using patient-specific respiratory traces and machine log files. Both were benchmarked against the Monte Carlo engine FRED. To demonstrate the methodology, the framework was applied to two clinical cases treated on the Mevion S250i system without rescanning. Dose accumulation incorporated respiratory phase, range ( ± 3%), and setup ( ± 5 mm) uncertainties. Main results. Excellent agreement was observed between TPS and FRED ( < 1% mean dose difference) and between predictive and a posteriori models ( < 2 % across DVH metrics). Cumulative dose distributions for the primary CTV converged after five fractions, confirming robust delivery. Significance. This automated, clinically integrated framework enables pre-treatment prediction and a posteriori validation of interplay and motion robustness in Pencil beam scanning plans. Preliminary results support its clinical utility, especially for hypofractionation and targets with large motion ( > 2 cm). A larger cohort study is ongoing and will be reported separately.


  • Open Access

    Resource sharing and open-source software in radiation oncology: From challenges to opportunities for community-wide benefit

    by Samuel Ingram, Lorenzo Brualla, Alexia Delbaere, Masoud Zarepisheh, Hendrik Piersma, Aditya Apte, Roman Ludwig, Erik Roelofs, Marcel Nachbar, Ali Zaila, et al.


  • Open Access

    Fast microdosimetry algorithms in particle therapy: Benchmark and applicability guidelines

    by Giorgio Cartechini, Marta Missiaggia, Francesco Giuseppe Cordoni

  • Open Access

    Machine Learning-Based Beam Delivery Time Model for Mevion S250i With Hyperscan Technology

    by Giorgio Cartechini, Francesco Giuseppe Cordoni, Mirko Unipan, Ilaria Rinaldi


  • Open Access

    Machine Learning-based beam delivery time model for Mevion 250i with Hyperscan technology

    by Giorgio Cartechini, Francesco Giuseppe Cordoni, Mirko Unipan, Ilaria Rinaldi

    Purpose: Accurate prediction of beam delivery time (BDT) is essential for operational efficiency, 4D dose calculations, and advanced proton therapy techniques. Despite its importance, no machine-specific BDT model exists for Mevion systems. Methods: We developed the first machine learning-based BDT model for the Mevion S250i Hyperscan system. Institutional machine log files from 11 patients (1120 files) were used to extract features including spot position, energy layer changes, Adaptive Aperture (AA) movements, and spot charge. Inter-pulse time ($Δ$T) was the target variable. A Random Forest model was trained with cross-validation and tested on held-out data. SHAP (Shapley Additive Explanations) analysis was used to quantify feature contributions. Results: The model achieved mean absolute errors (MAE) ranging from 0.9 ms for short intervals (1000 ms). AA movements were the dominant global predictor for $Δ$T > 50 ms, while spot positions and pulse charge influenced short intervals. Energy changes had minor global impact but locally contributed to large $Δ$T values, consistent with range modulator physics. The model was tested in two clinical applications: volumetric repainting and 4D dose recalculation for interplay evaluation. Predicted cumulative delivery times deviated by only -1.7% from machine log data, and dosimetric metrics (D98, D95, V95) remained within intrinsic delivery variability. Conclusions: This study presents the first machine-specific BDT model for the Mevion S250i, accurately capturing temporal dynamics and predictive performance. SHAP analysis provided insight into system behavior, highlighting the roles of AA adjustments, energy switching, and spot positioning. The model supports applications in interplay assessment, 4D dose calculation, and delivery time-based plan optimization.

  • Open Access

    Validation of the generalized stochastic microdosimetric model (GSM 2 ) over a broad range of LET and particle beam type: a unique model for accurate description of (therapy relevant) radiation qualities

    by Giulio Bordieri, Marta Missiaggia, Giorgio Cartechini, Marco Battestini, Lawrence Bronk, Fada Guan, David Grosshans, Priyamvada Rai, Emanuele Scifoni, Chiara La Tessa, et al.

    Objective. The present work shows the first extensive validation of the generalized stochastic microdosimetric model (GSM2). This mechanistic and probabilistic model is trained and tested over cell survival experiments conducted with two cell lines (H460 and H1437), three different types of radiation (protons, helium, and carbon ions), spanning a very broad LET range from 1   keV μ m − 1 up to more than 300   keV μ m − 1 . Currently, the existing mechanistic radiation biophysical models show some limitations in describing cell killing without the addition of ad hoc corrections, especially in the high-LET regime, where the overkill effect is observed. Approach. The experimental irradiation conditions have been accurately reproduced with Monte Carlo simulations using the GEANT4-based TOPAS computational toolkit. We show the main and unique features of GSM 2 , i.e. how it can predict the biological response by considering the full information on the stochasticity of radiation through the microdosimetric spectrum, which is supposed to be the best descriptor of radiation quality. Main results. Well-matching results for different biological endpoints with the natural presence of the overkill effect fully display the predictive power of GSM2. Significance. This study shows the complete generality and flexibility of GSM2 and its ability to successfully predict the cell survival probability from very different particle radiation fields. Consequently, we demonstrate the dependence of the relative biological effectiveness on the whole microdosimetric spectrum, which fully includes the stochasticity inherently given by radiation-matter interaction.


  • Open Access

    Integrating microdosimetric in vitro RBE models for particle therapy into TOPAS MC using the MicrOdosimetry-based modeliNg for RBE ASsessment (MONAS) tool

    by Giorgio Cartechini, Marta Missiaggia, Emanuele Scifoni, Chiara La Tessa, Francesco G Cordoni

    Objective. In this paper, we present MONAS (MicrOdosimetry-based modelliNg for relative biological effectiveness (RBE) ASsessment) toolkit. MONAS is a TOPAS Monte Carlo extension, that combines simulations of microdosimetric distributions with radiobiological microdosimetry-based models for predicting cell survival curves and dose-dependent RBE. Approach. MONAS expands TOPAS microdosimetric extension, by including novel specific energy scorers to calculate the single- and multi-event specific energy microdosimetric distributions at different micrometer scales. These spectra are used as physical input to three different formulations of the microdosimetric kinetic m odel , and to the generalized stochastic microdosimetric model (GSM 2 ), to predict dose-dependent cell survival fraction and RBE. MONAS predictions are then validated against experimental microdosimetric spectra and in vitro survival fraction data. To show the MONAS features, we present two different applications of the code: (i) the depth-RBE curve calculation from a passively scattered proton SOBP and monoenergetic 12 C-ion beam by using experimentally validated spectra as physical input, and (ii) the calculation of the 3D RBE distribution on a real head and neck patient geometry treated with protons. Main results. MONAS can estimate dose-dependent RBE and cell survival curves from experimentally validated microdosimetric spectra with four clinically relevant radiobiological models. From the radiobiological characterization of a proton SOBP and 12 C fields, we observe the well-known trend of increasing RBE values at the distal edge of the radiation field. The 3D RBE map calculated confirmed the trend observed in the analysis of the SOBP, with the highest RBE values found in the distal edge of the target. Significance. MONAS extension offers a comprehensive microdosimetry-based framework for assessing the biological effects of particle radiation in both research and clinical environments, pushing closer the experimental physics-based description to the biological damage assessment, contributing to bridging the gap between a microdosimetric description of the radiation field and its application in proton therapy treatment with variable RBE.


  • Does variable RBE affect toxicity risks for mediastinal lymphoma patients? NTCP-based evaluation after proton therapy treatment

    by Francesco Tommasino, Giorgio Cartechini, Roberto Righetto, Paolo Farace, Marco Cianchetti


  • Microdosimetric measurements as a tool to assess potential in-field and out-of-field toxicity regions in proton therapy

    by M Missiaggia, G Cartechini, E Scifoni, M Rovituso, F Tommasino, E Verroi, M Durante, C La Tessa

    Relative biological effectiveness (RBE) variations are thought to be one of the primary causes of unexpected normal-tissue toxicities during tumor treatments with charged particles. Unlike carbon therapy, where treatment planning is optimized on the basis of the RBE-weighted dose, a constant RBE value of 1.1 is currently used in proton therapy. Assuming a uniform value can lead to under- or over-dosage, not just to the tumor but also to surrounding normal tissue. RBE changes have been linked with dose/fraction, the biological endpoint and beam properties. Understanding radiation quality and the associated RBE can improve the prediction of normal-tissue toxicities. In this study, we exploited microdosimetry for characterizing radiation quality in proton therapy in-field, and off-beam at 20 (beam edge), 50 (close out-of-field) and 100 (far out-of-field) mm from the beam center. We measured the lineal energy y spectra in a water phantom irradiated with 152 MeV protons, from which beam quality as well as the physical dose could be obtained. Taking advantage of the linear quadratic model and a modified version of the microdosimetric kinetic model, the microdosimetric data were combined with radiobiological parameters ( α and β ) of human salivary gland tumor cells for assessing cell survival RBE and RBE-weighted dose. The results indicate that if a dose of 60 Gy is delivered to the peak, the beam edge receives up to 6 Gy while the close and far out-of-field regions receive doses on the order of 10 −3 Gy and 10 −4 Gy, respectively. The RBE estimate in-beam shows large variations, ranging from 1.0 ± 0.2 at the entrance channel to 2.51 ± 0.15 at the tail. The beam edge follows a similar trend but the RBE calculated at the Bragg peak depth is 2.27 ± 0.17, i.e. twice the RBE in-beam (1.05 ± 0.15). Out-of-field, the estimated RBE is always significantly higher than 1.1 and increases with increasing lateral distance, reaching the overall highest value of 3.4 ± 0.3 at a depth of 206 mm and a lateral distance of 10 mm. The combination of RBE and dose into the biological dose points to the beam edge and the end-of-range in-beam as the areas with the highest risk of potential toxicities.